First Time Loading...
T

Teva Pharmaceutical Industries Ltd
NYSE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Watchlist
Price: 14.43 USD 2.05% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. [ Read More ]

The intrinsic value of one TEVA stock under the Base Case scenario is 15.15 USD. Compared to the current market price of 14.43 USD, Teva Pharmaceutical Industries Ltd is Undervalued by 5%.

Key Points:
TEVA Intrinsic Value
Base Case
15.15 USD
Undervaluation 5%
Intrinsic Value
Price
T
Worst Case
Base Case
Best Case

Valuation Backtest
Teva Pharmaceutical Industries Ltd

Backtest TEVA Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TEVA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Company Boosts Revenue Outlook for 2023
2023-Q2 Earnings Call

Company Boosts Revenue Outlook for 2023

The company's revenue grew by 4% to $3.9 billion, with a strengthened adjusted EBITDA at $1.1 billion, leading to an increase in the revenue outlook for 2023 to a range of $15 billion to $15.4 billion. Notable growth was seen in its innovative treatments AUSTEDO and AJOVY, with AUSTEDO revenues jumping 51% for the quarter and AJOVY growing by 17%, contributing to overall international growth. The company confirmed its full-year free cash flow guidance of $1.7 billion to $2.1 billion and aims to significantly reduce net debt, which stands at $18 billion, working towards a targeted net debt to EBITDA ratio of two times by the end of 2027.

Financials

Balance Sheet Decomposition
Teva Pharmaceutical Industries Ltd

Current Assets 12.5B
Cash & Short-Term Investments 3.2B
Receivables 3.4B
Other Current Assets 5.9B
Non-Current Assets 31B
PP&E 6.1B
Intangibles 22.6B
Other Non-Current Assets 2.3B
Current Liabilities 12.2B
Accounts Payable 2.6B
Accrued Liabilities 3.4B
Short-Term Debt 23m
Other Current Liabilities 6.2B
Non-Current Liabilities 23.7B
Long-Term Debt 18.2B
Other Non-Current Liabilities 5.6B
Efficiency

Earnings Waterfall
Teva Pharmaceutical Industries Ltd

Revenue
15.8B USD
Cost of Revenue
-7.9B USD
Gross Profit
8B USD
Operating Expenses
-4.4B USD
Operating Income
3.5B USD
Other Expenses
-4.1B USD
Net Income
-559m USD

Free Cash Flow Analysis
Teva Pharmaceutical Industries Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TEVA Profitability Score
Profitability Due Diligence

Teva Pharmaceutical Industries Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive Operating Income
Positive Free Cash Flow
46/100
Profitability
Score

Teva Pharmaceutical Industries Ltd's profitability score is 46/100. The higher the profitability score, the more profitable the company is.

TEVA Solvency Score
Solvency Due Diligence

Teva Pharmaceutical Industries Ltd's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Short-Term Solvency
High D/E
Positive Net Debt
27/100
Solvency
Score

Teva Pharmaceutical Industries Ltd's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TEVA Price Targets Summary
Teva Pharmaceutical Industries Ltd

Wall Street analysts forecast TEVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TEVA is 15.13 USD .

Lowest
Price Target
Not Available
Average
Price Target
15.13 USD
5% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

TEVA Price
Teva Pharmaceutical Industries Ltd

1M 1M
+11%
6M 6M
+36%
1Y 1Y
+67%
3Y 3Y
+37%
5Y 5Y
-7%
10Y 10Y
-68%
Annual Price Range
5 268
52w Low
2 661
52w High
5 268
Price Metrics
Average Annual Return -10%
Standard Deviation of Annual Returns 28.2%
Max Drawdown -62%
Shares Statistics
Market Capitalization 59.5B ILS
Shares Outstanding 11 256 860
Percentage of Shares Shorted
N/A

TEVA Return Decomposition
Main factors of price return

What is price return decomposition?

TEVA News

Other Videos

Last Important Events
Teva Pharmaceutical Industries Ltd

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Teva Pharmaceutical Industries Ltd

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Teva Pharmaceutical Industries Ltd

Country

Israel

Industry

Pharmaceuticals

Market Cap

59.5B USD

Dividend Yield

0%

Description

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Contact

Petah Tikva
5 Bazel St, P O B 3190
+97239267267.0
http://www.tevapharm.com

IPO

1951-01-01

Employees

37 037

Officers

Executive VP & CFO
Mr. Eliyahu Sharon Kalif
Executive Vice President of Global Operations
Mr. Eric Drape
Executive Vice President of International Markets Commercial
Mr. Mark Sabag
President, CEO & Director
Mr. Richard D. Francis
Senior VP & Chief Accounting Officer
Mr. Amir Weiss
Head of Investor Relations
Ran Meir
Show More
Acting Chief Legal Officer & Corporate Secretary
Dov Bergwerk
Senior Vice President, Global Compliance & Ethics Officer
Kathleen Veit
Acting Head of Global Human Resources
Ms. Vikki Conway
Senior Vice President of Investor Relations
Mr. Kevin C. Mannix
Show Less

See Also

Discover More
What is the Intrinsic Value of one TEVA stock?

The intrinsic value of one TEVA stock under the Base Case scenario is 15.15 USD.

Is TEVA stock undervalued or overvalued?

Compared to the current market price of 14.43 USD, Teva Pharmaceutical Industries Ltd is Undervalued by 5%.